On June 11, M2D2 Resident Company Glyscend Therapeutics announced the closing of a Series A financing round valued at $20.5 million. Glyscend will use this funding to further support the development of its novel oral polymer therapy for patients with type 2 diabetes, as well as other metabolic diseases.Continue reading
During the second week of June, two M2D2 resident companies took part in this year’s BIO Digital Convention. LivOnyx Inc. and Versatope Therapeutics both presented their progress and innovative solutions during BIO Digital Week, a virtual convention featuring interactive sessions covering therapeutics, digital health, patient advocacy, and more. Both of these startups are working on solutions that are very relevant during the COVID-19 pandemic.Continue reading
M2D2 Resident Company Versatope and Netherlands-based Intravacc announced on June 8th, that they have signed a research service agreement to further develop a universal vaccine against influenza. The vaccine will be based on Intravacc’s innovative Outer Membrane Vesicles (OMV) technology, which is proven to be safe in humans.Continue reading
We are always excited to share the news about our resident companies’ successes. Tuesday morning, LaunchPad Medical announced that they received support up to $1.8 million from the Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center. It was funded by the National Institute of Dental and Cranial Research to improve the translation of promising tissue engineering and regenerative medicine technologies for dental, oral, and craniofacial clinical practice.Continue reading
Our 15 finalists for the 2020 $200K Challenge have innovative, lifesaving ideas. While we wait for a safer time to reschedule the Challenge, we will continue to share our finalists’ life sciences innovations.
$200K Challenge Finalist CranioSense is developing IPASS, a medical device for noninvasive assessment of intracranial pressure (ICP), a critical parameter in traumatic brain injury (TBI) and other medical conditions affecting the brain. We talked with CEO Gordon Hirschman about what brought them to their innovation and the 2020 $200K Challenge.Continue reading
As we wait for a safer time to reschedule the 2020 $200K Challenge events, we want to share our Finalists’ new, lifesaving ideas.
$200K Challenge Amachumu Bio is a socially minded, globally focused company working to create healthier and more productive communities by curing 1.5 billion people and food and companion animals of intestinal parasitic worms. We talked with CEO Meghan Doyle and founder Raffi Aroian about their company’s history and their innovative food supplement that aims to address the problem.Continue reading
Two years ago, Cam Med Inc. was a Finalist in the 2018 M2D2 $200K Challenge. Since then, Cam Med’s cofounders, CEO Larry Alberts and CTO Zhifei Ge have been the very model of “seize every opportunity” startup leaders, taking advantage of virtually every chance for learning, mentoring, financing, and networking that’s come their way. The result has been a steady upward trajectory for their innovation: the Evopump, a wearable on-body delivery system for injectable drugs.Continue reading
In March, we chose 15 innovative startups as M2D2 $200K Challenge Finalists for 2020. While we have had to postpone the Challenge events in response to the COVID-19 pandemic, we don’t want to wait to share our Finalists’ new, lifesaving ideas.
$200K Challenge Finalist Arrow Diagnostics, Inc. is working towards non-invasive solutions for early screening of non-alcoholic fatty liver disease. We talked to Edward Olano, co-founder and CEO, about their history and their innovation.Continue reading
We’re not letting a pandemic get between you and the expertise you need to advance your idea. In fact we’re now able to connect anyone with life sciences advisors with Virtual Office Hours.
Starting Tuesday, April 14th, our Insider Advisors will begin hosting Virtual Office Hours using Zoom. Leading off will be Jeff Champagne from MPR and Barry Sands from RQMIS, Inc. Throughout the coronavirus emergency, we will coordinate with our other life sciences advisors so we can continue to offer startups a broad range of expertise and assistance.Continue reading